The drivers of recurrence and resistance in ovarian high grade serous carcinoma remain
unclear. We investigate the acquisition of resistance by collecting tumour biopsies from a …

Cancer is the leading cause of disease related death in teenagers and young adults (TYAs)
in Western countries. 1 2 In the UK, cancer in TYAs accounts for 9% and 15% of all male and …

BackgroundPathological response to neoadjuvant treatment for patients with high-grade
serous ovarian carcinoma (HGSOC) is assessed using the chemotherapy response score (CRS…

Background Ovarian cancer survival rates have not changed in the last 20 years. The
majority of cases are High-grade serous ovarian carcinomas (HGSOCs), which are typically …

Purpose To develop a precision tissue sampling technique that uses computed tomography
(CT)–based radiomic tumour habitats for ultrasound (US)-guided targeted biopsies that can …

Simple Summary The extraction of quantitative data from standard-of-care imaging modalities
offers opportunities to improve the relevance and salience of imaging biomarkers used in …

Epithelial ovarian carcinoma (EOC) encompasses distinct histological, molecular and
genomic entities that determine intrinsic sensitivity to platinum-based chemotherapy. Current …

Whole‐genome sequencing (WGS) of circulating tumour DNA (ctDNA) is now a clinically
important biomarker for predicting therapy response, disease burden and disease progression. …

High grade serous ovarian carcinoma (HGSOC) is a highly heterogeneous disease that
typically presents at an advanced, metastatic state. The multi-scale complexity of HGSOC is a …

High-grade serous ovarian carcinoma (HGSOC) is characterised by poor outcome and extreme
chromosome instability (CIN). Therapies targeting centrosome amplification (CA), a key …